- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01097148
Peri -and Postoperative Drug Therapy Schedules for Morbidly Obese Patients (POP-II)
Rationale: Obesity is an increasing health risk worldwide, with the USA recording prevalence in adults of around 20%. The mean body weight of obese patients is also increasing. One of the strategies to treat extreme obesity (Body Mass Index (BMI) > 40 kg/m2) is weight-reducing surgery like laparoscopic gastric banding or gastric bypass. During anaesthesia, morbidly obese patients are exposed to an increased risk at developing postoperative wound infections, apnoea and thrombotic events and may be more difficult to intubate. Routinely, amongst others, cefazolin, morphine, nadroparin and atracurium are administered in standard dosages. However, it is not known to what extend the pharmacokinetics and/or -dynamics of these drugs are affected in morbidly obese patients. Therefore, evidence-based dosing schedules for these drugs in morbidly obese patients should be developed.
Objective: The study is performed in order to develop population pharmacokinetic and/or pharmacodynamic models of the routinely used drug therapies during bariatric surgery in morbidly obese patients (BMI > 40 kg/m2): cefazolin, morphine, nadroparin and atracurium.
A covariate analysis will be performed in order to account for variability in pharmacokinetic and/or pharmacodynamic parameters. This covariate analysis will take into account procedure and patient bound covariates, with specific interest for body weight as a covariate. Whenever possible, non-obese patients will be included in the covariate analysis.
The results will be used to develop individualised dosing schemes for routinely used drugs peri-operatively in morbidly obese patients.
Study design: A randomised, prospective, observational, therapeutic and invasive study.
Study population: Morbidly obese patients with a Body Mass Index > 40 kg/m2 undergoing laparoscopic banding or gastric bypass surgery, 18-60 years old. A total of 20 patients will be included in the study.
Intervention (if applicable): All measurements and data collection will take place around administration of drugs that are given according to routine clinical practice (cefazolin 2 grams for prophylaxis of infections, morphine 10 mg intravenously at the end of surgery, a patient-controlled analgesia (PCA) pump with morphine for postoperative pain relief and nadroparin 0,6 ml for trombo-embolic prophylaxis). For muscle relaxation, patients are randomised to receive one of two generally accepted dosing regimen of atracurium (0.5 mg/kg based on ideal body weight or 0.5 mg/kg based on total body weight). Peri- and postoperatively, a maximum amount of 70 ml of blood will be collected from an indwelling arterial line for measurement of concentrations of cefazolin, morphine, and anti-Xa (nadroparin). One week after surgery the patient will be checked for thrombosis using ultrasonography.
Main study parameters/endpoints:
Primary endpoints to evaluate in morbidly obese patients are;
- pharmacokinetic parameters of cefazolin in blood;
- pharmacokinetic parameters of morphine and metabolites in blood;
- time course of anti-factor Xa levels in blood following nadroparin;
- time course of the pharmacodynamic effect of atracurium.
Secondary endpoints to evaluate in morbidly obese patients are:
- to compare primary endpoints (obtained in morbidly obese patients) with data of non-obese patients
- the occurrence of postoperative wound infections;
- postoperative pain scores, sedation scores and nausea scores;
- the occurrence of bleedings or thrombotic events ;
- required amounts of morphine (PCA);
- to compare the time course of the pharmacodynamic effect of two different doses of atracurium.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
NIeuwegein, Netherlands, 3435EM
- St. Antonius Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Morbidly obese patients undergoing bariatric surgery with a BMI > 40 kg/m2, ASA I-III
Exclusion Criteria:
- Epilepsy, pregnancy, breastfeeding and known allergy allergies to cefazolin, morphine, nadroparin, atracurium, or benzene sulphonic acid. History of coagulation disorder or history of heparin/LMWH induced thrombocytopenia.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Atracurium, TBW
Dose of atracurium 0.5 mg/kg based on total body weight
|
Dose atracurium 0.5 mg/kg based on total body weight
|
ACTIVE_COMPARATOR: Atracurium IBW
dose 0.5 mg/kg based on ideal body weight
|
Dose atracurium 0.5 mg/kg based on total body weight
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time course of the pharmacodynamic effect of atracurium
Time Frame: 6 months
|
6 months
|
Pharmacokinetic parameters of cefazolin in blood
Time Frame: 6 months
|
6 months
|
Pharmacokinetic parameters of morphine and metabolites in blood
Time Frame: 6 months
|
6 months
|
Time course of anti-factor Xa levels in blood following nadroparin
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Dosing of atracurium based on total or ideal body weight
Time Frame: 6 months
|
6 months
|
To compare primary endpoints (obtained in morbidly obese patients) with data of non-obese patients
Time Frame: 6 months
|
6 months
|
The occurrence of postoperative wound infections
Time Frame: 6 months
|
6 months
|
Postoperative pain scores, sedation scores and nausea scores
Time Frame: 6 months
|
6 months
|
The occurrence of bleedings or thrombotic events
Time Frame: 6 months
|
6 months
|
Required amounts of morphine (PCA)
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Simone van Kralingen, MD, St. Antonius Hospital
Publications and helpful links
General Publications
- de Hoogd S, Valitalo PAJ, Dahan A, van Kralingen S, Coughtrie MMW, van Dongen EPA, van Ramshorst B, Knibbe CAJ. Influence of Morbid Obesity on the Pharmacokinetics of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide. Clin Pharmacokinet. 2017 Dec;56(12):1577-1587. doi: 10.1007/s40262-017-0544-2.
- Diepstraten J, Janssen EJ, Hackeng CM, van Dongen EP, Wiezer RJ, van Ramshorst B, Knibbe CA. Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint. Eur J Clin Pharmacol. 2015 Jan;71(1):25-34. doi: 10.1007/s00228-014-1760-4. Epub 2014 Oct 12.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Overnutrition
- Nutrition Disorders
- Overweight
- Body Weight
- Obesity
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Cholinergic Antagonists
- Cholinergic Agents
- Neuromuscular Agents
- Nicotinic Antagonists
- Neuromuscular Nondepolarizing Agents
- Neuromuscular Blocking Agents
- Atracurium
Other Study ID Numbers
- V.09.231/R-09
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obese
-
Zagazig UniversityCompletedAbdominal Surgery | Obese PatientsEgypt
-
University Hospital, GhentCompleted
-
Bristol-Myers SquibbCompletedObese But Otherwise Healthy ParticipantsUnited States
-
University Hospital, Clermont-FerrandUnknownObese Adolescent | Elite Adolescent AthletesFrance
-
Beth Israel Deaconess Medical CenterCompletedObese | Lean | Obese DiabeticsUnited States
-
Hospital Clinic of BarcelonaTerminatedObese Pregnant WomenSpain
-
Sabrin Mohamed Taha AbdelwahabCompletedObese Women With PCOSEgypt
-
University Hospital, Clermont-FerrandUnknown
-
Eisai Inc.CompletedPharmacokinetics in Obese AdolescentsUnited States
Clinical Trials on Atracurium, TBW
-
Oslo University HospitalActive, not recruiting
-
Massachusetts Eye and Ear InfirmaryOregon Health and Science University; National Institute on Deafness and Other... and other collaboratorsEnrolling by invitationMigraine | Dizziness | Motion Sickness | Vestibular Migraine | Vestibular Schwannoma | Vestibular DisorderUnited States
-
Mansoura UniversityRecruiting
-
CHU de ReimsVerathonCompletedTracheal IntubationFrance
-
Sir Ganga Ram HospitalUnknownPatients Undergoing Laparoscopic SurgeryIndia
-
Isfahan University of Medical SciencesCompletedIntraocular PressureIran, Islamic Republic of
-
Hopital FochTerminated
-
Leiden University Medical CenterCompletedRenal Disease | Prostate HypertrophyNetherlands
-
China International Neuroscience InstitutionCompleted
-
Chonnam National University HospitalUnknownNeuromuscular BlockadeKorea, Republic of